Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Theravance has said that GlaxoSmithKline has initiated subject screening in a Phase I clinical study designed to assess the safety, tolerability, and pharmacokinetics of an investigational, inhaled bronchodilator, GSK1160724, for the treatment of chronic obstructive pulmonary disease.
Subscribe to our email newsletter
GSK1160724 is a long-acting muscarinic antagonist (LAMA) discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. The LAMA program is one of three respiratory programs under joint development by GlaxoSmithKline (GSK) and Theravance.
Michael Kitt, senior vice president of development at Theravance, said: “The goal of our program is to develop an effective once-a-day inhaled medicine that is better tolerated than the market leaders. In addition, at higher doses, a more lung-selective LAMA might offer improved efficacy with comparable or improved tolerability.”